182 related articles for article (PubMed ID: 38139411)
1. Mesenchymal-Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis.
Moraes FCA; Vilbert M; Alves VFC; de Oliveira Almeida G; Priantti JN; Madeira T; Stecca C; Fernandes MR; Dos Santos NPC
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139411
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
[TBL] [Abstract][Full Text] [Related]
4. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
[TBL] [Abstract][Full Text] [Related]
5. Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.
Albiges L; Heng DYC; Lee JL; Walker S; Mellemgaard A; Ottesen L; Frigault MM; L'Hernault A; Wessen J; Choueiri T; Cancel M; Signoretti S
Eur J Cancer; 2022 Jul; 170():158-168. PubMed ID: 35640484
[TBL] [Abstract][Full Text] [Related]
6. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
[TBL] [Abstract][Full Text] [Related]
8. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
[TBL] [Abstract][Full Text] [Related]
9. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
10. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
Chen Q; Cheng L; Li Q
Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
[No Abstract] [Full Text] [Related]
11. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.
Gordon MS; Hussey M; Nagle RB; Lara PN; Mack PC; Dutcher J; Samlowski W; Clark JI; Quinn DI; Pan CX; Crawford D
J Clin Oncol; 2009 Dec; 27(34):5788-93. PubMed ID: 19884559
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma.
Rosette KA; Lander SM; VanOpstall C; Looyenga BD
Am J Physiol Renal Physiol; 2021 Jul; 321(1):F33-F46. PubMed ID: 34029144
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Resch I; Enikeev D; Karakiewicz PI; Shariat SF; Schmidinger M
Urol Oncol; 2021 Nov; 39(11):764-773. PubMed ID: 34400065
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of perioperative appliance of sunitinib in patients with metastatic or advanced renal cell carcinoma: A systematic review and meta-analysis.
Jin H; Zhang J; Shen K; Hao J; Feng Y; Yuan C; Zhu Y; Ma X
Medicine (Baltimore); 2019 May; 98(20):e15424. PubMed ID: 31096438
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
[TBL] [Abstract][Full Text] [Related]
19. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
20. Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease.
Chan E; Stohr BA; Butler RS; Cox RM; Myles JL; Nguyen JK; Przybycin CG; Reynolds JP; Williamson SR; McKenney JK
Am J Surg Pathol; 2022 Mar; 46(3):392-403. PubMed ID: 34881751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
